Flexible or fixed: A comparative review of linear and cyclic cancer-targeting peptides

Future Medicinal Chemistry

Volumn 4, Issue 12, 2012, Pages 1601-1618

  Roxin, Áron ^a,b   Zheng, Gang ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERMEDIN; AMINO ACID; ANTINEOPLASTIC AGENT; ARGINYLGLYCYLASPARTIC ACID; BIOLOGICAL MARKER; CARBOHYDRATE; CELL PENETRATING PEPTIDE; CYCLOPEPTIDE; CYSTEINE; DOXORUBICIN; HISTIDINE; INDIUM 111; INTEGRIN; IODINE 125; LINEAR PEPTIDE; NANOPARTICLE; PACLITAXEL; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RHENIUM; SYNTHETIC PEPTIDE; TECHNETIUM 99M; TETRAXETAN; TRACER; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VITRONECTIN RECEPTOR;

AMINO ACID SEQUENCE; BINDING AFFINITY; CANCER PEPTIDE THERAPY; CANCER THERAPY; CELL CYCLE; CYCLIZATION; DRUG CONJUGATION; ENZYME INHIBITION; EPIFLUORESCENCE MICROSCOPY; FLUORESCENCE ACTIVATED CELL SORTING; GEOMETRY; HUMAN; ISOTOPE LABELING; LIGAND BINDING; MOLECULAR IMAGING; MOLECULARLY TARGETED THERAPY; NONHUMAN; PEPTIDE ANALYSIS; PEPTIDE CYCLIZATION; PEPTIDE LIBRARY; PEPTIDE SYNTHESIS; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; RECEPTOR BINDING; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; TUMOR CELL; TUMOR XENOGRAFT;

ANIMALS; CELL-PENETRATING PEPTIDES; CYCLIZATION; HUMANS; NEOPLASMS; PEPTIDES; PEPTIDES, CYCLIC; PROTEIN BINDING; RECEPTORS, CELL SURFACE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84865514143     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.12.75     Document Type: Review

References (95)

1. Liskamp RMJ, Rijkers DTS, Bakker SE. Charpter 1. Bioactive macrocyclic peptides and peptide mimics. In: Modern Supramolecular Chemistry: Strategies for Macrocycle Synthesis. Diederich F, Stang PJ, Tykwinski RR (Eds). Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, Germany, 1-28 (2008).
2. D'Andrea LD, Iaccarino G, Fattorusso R et al. Targeting angiogenesis: structural characterization and biological properties of a de novo engineered VEGF mimicking peptide. Proc. Natl Acad. Sci. USA 102(40), 14215-14220 (2005). (Pubitemid 41429678)
3. Kessler H. Conformation and biological activity of cyclic peptides. Angew. Chem. Int. Ed. Engl. 21, 512-523 (1982).
4. Ramakrishnan C, Paul PKC, Ramnarayan K. Cyclic peptides - small and big and their conformational aspects. J. Biosci. 8, 239-251 (1985).
5. Deber CM, Madison V, Blout ER. Why cyclic peptides? Complementary approaches to conformations. Acc. Chem. Res. 9(3), 106-113 (1976).
6. Grünewald J, Marahiel MA. Chemoenzymatic and template-directed synthesis of bioactive macrocyclic peptides. Microbiol. Mol. Biol. Rev. 70(1), 121-146 (2006).
7. Aina OH, Sroka TC, Chen ML, Lam KS. Therapeutic cancer targeting peptides. Biopolymers 66(3), 184-199 (2002). (Pubitemid 35285218)
8. Blout ER. Cyclic peptides: past, present, and future. Biopolymers 20, 1901-1912 (1981).
9. Deem MW, Bader JS. A configurational bias Monte Carlo method for linear and cyclic peptides. Mol. Phys. 87(6), 1245-1260 (1996). (Pubitemid 126467110)
10. Lee M, Gardner B, Kahn M, Nakanishi H. The three-dimensional solution structure of a constrained peptidomimetic in water and in chloroform - observation of solution-induced hydrophobic cluster. FEBS Lett. 359, 113-118 (1995).
11. Uma K, Kishore R, Balaram P. Stereochemical constraints in peptide design: analysis of the influence of a disulfide bridge and an α-aminoisobutyryl residue on the conformation of a hexapeptide. Biopolymers 33(6), 865-871 (1993). (Pubitemid 23184422)
12. Lau D, Guo L, Liu R, Marik J, Lam K. Peptide ligands targeting integrin a3b1 in non-small cell lung cancer. Lung Cancer 52(3), 291-297 (2006). (Pubitemid 43674548)
13. Kopple KD. Synthesis of cyclic peptides. J. Pharm. Sci. 61(9), 1345-1356 (1972).
14. Lambert JN, Mitchell JP, Roberts KD. The synthesis of cyclic peptides. J. Chem. Soc. Perkin. Trans. 1, 471-484 (2001).
15. Davies JS. The cyclization of peptides and depsipeptides. J. Pept. Sci. 9(8), 471-501 (2003). (Pubitemid 37009926)
16. White CJ, Yudin AK. Contemporary strategies for peptide macrocyclization. Nat. Chem. 3, 509-524 (2011).
17. Kumar A, Ye G, Wang Y, Lin X, Sun G, Parang K. Synthesis and structure-activity relationships of linear and conformationally constrained peptide analogues of CIYKYY as Src tyrosine kinase inhibitors. J. Med. Chem. 49(11), 3395-3401 (2006). Most cyclic CIYKYY-analogues were more potent that the original linear Ac-CIYKYY peptide for Src tyrosine kinase inhibition. (Pubitemid 43830538)
18. Assa-Munt N, Jia X, Laakkonen P, Ruoslahti E. Solution structures and integrin binding activities of an RGD peptide with two isomers. Biochemistry 40(8), 2373-2378 (2001). (Pubitemid 32171709)
19. García-Aranda MI, Mirassou Y, Gautier B et al. Disulfide and amide-bridged cyclic peptide analogues of the VEGF81-91 fragment: synthesis, conformational analysis and biological evaluation. Bioorg. Med. Chem. 19(24), 7526-7533 (2011).
20. Gallop MA, Barrett RW, Dower WJ, Fodor SPA, Gordon EM. Applications of combinatorial technologies to drug discovery. 1. Backgroud and peptide combinatorial libraries. J. Med. Chem. 37(9), 1233-1251 (1994). (Pubitemid 24179463)
21. Scott CP, Abel-Santos E, Jones AD, Benkovic SJ. Structural requirements for the biosynthesis of backbone cyclic peptide libraries. Chem. Biol. 8(8), 801-815 (2001). (Pubitemid 32752459)
22. Aina OH, Marik J, Liu R, Lau DH, Lam KS. Identification of novel targeting peptides for human ovarian cancer cells using "one-bead one-compound" combinatorial libraries. Mol. Cancer Ther. 4(5), 806-813 (2005). (Pubitemid 40767125)
23. Aina OH, Liu R, Sutcliffe JL, Marik J, Pan CX, Lam KS. From combinatorial chemistry to cancer-targeting. Mol. Pharm. 4(5), 631-651 (2007).
24. Bonetto S, Spadola L, Buchanan AG, Jermutus L, Lund J. Identification of cyclic peptides able to mimic the functional epitope of IgG1-Fc for human FcgRI. FASEB J. 23(2), 575-585 (2009).
25. Hsiao JR, Chang Y, Chen YL et al. Cyclic avb6-targeting peptide selected from biopanning with clinical potential for head and neck squamous cell carcinoma. Head Neck 32, 160-172 (2010). The cyclic cRGD peptide was more potent than the linear RGD peptide for inhibiting the growth of HSC-3 cells and the inactive linear RGE peptide became more potent upon cyclization.
26. Duncan KE, Dempsey BR, Killip LE et al. Discovery and characterization of a nonphosphorylated cyclic peptide inhibitor of the peptidylprolyl isomerase, Pin1. J. Med. Chem. 54(11), 3854-3865 (2011).
27. Pomilio AB, Battista SM, Vitale AA. Quantitative structure-activity relationship (QSAR) studies on bioactive cyclopeptides. In: QSPR-QSAR Studies on Desired Properties for Drug Design. Castro EA (Ed.). Research Signpost, Kerala, India, 1-34 (2010).
28. Andrews MJI, McInnes C, Kontopidis G et al. Design, synthesis, biological activity and structural analysis of cyclic peptide inhibitors targeting the substrate recruitment site of cyclin-dependent kinase complexes. Org. Biomol. Chem. 2(19), 2735-2741 (2004).
29. Zhou Y, Chakraborty S, Liu S. Radiolabeled cyclic RGD peptides as radiotracers for imaging tumors and thrombosis by SPECT. Theranostics 1, 58-82 (2011).
30. Pfaff M, Tangemanno K, Mullero B et al. Selective recognition of cyclic RGD peptides of NMR defined conformation by aIIbb3, avb3, and a5b1 integrins. J. Biol. Chem. 269(32), 20233-20238 (1994). (Pubitemid 24260416)
31. Haubner R, Gratias R, Diefenbach B, Goodman SL, Jonczyk A, Kessler H. Structural and functional aspects of RGD-containing cyclic pentapeptides as highly potent and selective integrin avb3 antagonists. J. Am. Chem. Soc. 118(32), 7461-7472 (1996). (Pubitemid 26279800)
32. Bach AC, Espina JR, Jackson SA et al. Type II to type I b-turn swap changes specificity for integrins. J. Am. Chem. Soc. 118(1), 293-294 (1996).
33. Wermuth J, Goodman SL, Jonczyk A, Kessler H. Stereoisomerism and biological activity of the selective and superactive avb3 integrin inhibitor cyclo (-RGDfV-) and its retroinverso peptide. J. Am. Chem. Soc. 119(6), 1328-1335 (1997). (Pubitemid 27122060)
34. Gilon C, Halle D, Chorev M, Selinger Z, Byk G. Backbone cyclization: a new method for conferring conformational constraint on peptides. Biopolymers 31(6), 745-750 (1991).
35. Bogdanowich-Knipp SJ, Jois DS, Siahaan TJ. The effect of conformation on the solution stability of linear vs. cyclic RGD peptides. J. Pept. Res. 53(5), 523-529 (1999). (Pubitemid 29287766)
36. Bogdanowich-Knipp SJ, Chakrabarti S, Williams TD, Dillman RK, Siahaan TJ. Solution stability of linear vs. cyclic RGD peptides. J. Pept. Res. 53(5), 530-541 (1999). (Pubitemid 29287767)
37. Yang L, Berk SC, Rohrer SP et al. Synthesis and biological activities of potent peptidomimetics selective for somatostatin receptor subype 2. Proc. Natl Acad. Sci. USA 95, 10836-10841 (1998). (Pubitemid 28413155)
38. Diel F, Borck H, Hosenfeld S. Effects of somatostatin on ethanol-induced gastric erosions in the rat: role of mast cells. Agents Actions 18, 273-275 (1986). (Pubitemid 16113275)
39. Vécsei L, Bollók I, Varga J, Penke B, Telegdy G. The effects of somatostatin, its fragments and an analog on electroconvulsive shock-induced amnesia in rats. Neuropeptides 4, 137-143 (1984). (Pubitemid 14131213)
40. Rosenburg JM. Octreotide: a synthetic analog of somatostatin. Ann. Pharmacother. 22, 748-754 (1988).
41. Evers BM, Parekh D, Townsend CM, Thompson JC. Somatostatin and analogues in the treatment of cancer. Ann. Surg. 213(3), 190-198 (1991).
42. Anthony L, Freda PU. From somatostatin to octreotide LAR: evolution of a somatostatin analogue. Curr. Med. Res. Opin. 12(12), 2989-2999 (2009).
43. Besser D, Müller B, Kleinwächter P et al. Synthesis and characterization of octapeptide somatostatin analogues with backbone cyclization: comparison of different strategies, biological activities and enzymatic stabilities. J. Prakt. Chem. 342(6), 537-545 (2000).
44. Pakkala M, Hekim C, Soininen P et al. Activity and stability of human kallikrein-2-specific linear and cyclic peptide inhibitors. J. Pept. Sci. 13(5), 348-353 (2007). The head-to-tail cyclized KLK2b derivatives were more biologically active and stable compared with the linear and disulfide-cyclized derivatives. (Pubitemid 46730574)
45. Ma X, Wu C, Wang W, Li X. Peptides from plants: a new source for antitumor drug research. Asian J. Trad. Med. 1(2), 85-90 (2006).
46. Namjoshi S, Benson HAE. Cyclic peptides as potential therapeutic agents for skin disorders. Biopolymers 94(5), 673-680 (2010).
47. Aneiros A, Garateix A. Bioactive peptides from marine sources: pharmacological properties and isolation procedures. J. Chromatogr. B. 803(1), 41-53 (2004). (Pubitemid 38340637)
48. Liu Z, Wang F, Chen X. Integrin avb3-targeted cancer therapy. Drug Dev. Res. 69(6), 329-339 (2008).
49. Oyston PCF, Fox MA, Richards SJ, Clark GC. Novel peptide therapeutics for treatment of infections. J. Med. Microbiol. 58(8), 977-987 (2009).
50. Schwartsmann G, Brondani da Rocha A, Berlinck RG, Jimeno J. Marine organisms as a source of new anticancer agents. Lancet Oncol. 2(4), 221-225 (2001). (Pubitemid 33585934)
51. Zilberberg L, Shinkaruk S, Lequin O et al. Structure and inhibitory effects on angiogenesis and tumor development of a new vascular endothelial growth inhibitor. J. Biol. Chem. 278(37), 35564-35573 (2003). (Pubitemid 37102329)
52. Haier J, Goldmann U, Hotz B, Runkel N, Keilholz U. Inhibition of tumor progression and neoangiogenesis using cyclic RGD-peptides in a chemically induced colon carcinoma in rats. Clin. Exp. Metastas. 19(8), 665-672 (2002). (Pubitemid 36092261)
53. Eskens FALM, Dumez H, Hoekstra R et al. Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins avb3 and avb5 in patients with advanced solid tumours. Eur. J. Cancer 39(7), 917-926 (2003). (Pubitemid 36428623)
54. Raguse JD, Gath HJ, Bier J, Riess H, Oettle H. Cilengitide (EMD 121974) arrests the growth of a heavily pretreated highly vascularised head and neck tumour. Oral. Oncol. 40(2), 228-230 (2004). (Pubitemid 38030369)
55. Gilbert MR, Kuhn J, Lamborn KR et al. Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a Phase II trial with measures of treatment delivery. J. Neurooncol. 106(1), 147-153 (2012).
56. Haubner R, Wester HJ, Burkhart F et al. Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J. Nucl. Med. 42(2), 326-336 (2001). (Pubitemid 32150525)
57. Achilefu S, Bloch S, Markiewicz MA et al. Synergistic effects of light-emitting probes and peptides for targeting and monitoring integrin expression. Proc. Natl Acad. Sci. USA 102(22), 7976-7981 (2005). (Pubitemid 40781048)
58. Okarvi SM. Peptide-based radiopharmaceuticals: future tools for diagnostic imaging of cancers and other diseases. Med. Res. Rev. 24(3), 357-397 (2004). (Pubitemid 38495786)
59. Lundqvist H, Tolmachev V. Targeting peptides and positron emission tomography. Biopolymers 66, 381-392 (2002). (Pubitemid 36433533)
60. Warner RRP, O'Dorisio TM. Radiolabeled peptides in diagnosis and tumor imaging: clinical overview. Semin. Nucl. Med. 32(2), 79-83 (2002). (Pubitemid 34311073)
61. Fani M, Psimadas D, Zikos C et al. Comparative evaluation of linear and cyclic 99mTc-RGD peptides for targeting of integrins in tumor angiogenesis. Anticancer Res. 26, 431-434 (2006). The cyclic 99mTc-radiolabeled RGDfKH peptide had a higher tumor accumulation than the linear analogue in MDA-MB 435 breast cancer mouse xenograft models. (Pubitemid 43206109)
62. Liu S. Radiolabeled cyclic RGD peptides as integrin avb3-targeted radiotracers: maximizing binding affinity via bivalency. Bioconjugate Chem. 20(12), 2199-2213 (2009).
63. Chen J, Cheng Z, Owen NK et al. Evaluation of an 111In-DOTA-rhenium cyclized α-MSH analog: a novel cyclic-peptide analog with improved tumor-targeting properties. J. Nucl. Med. 42(12), 1847-1855 (2001). (Pubitemid 34016356)
64. Raha S, Paunesku T, Woloschak G. Peptide-mediated cancer targeting of nanoconjugates. WIREs Nanomed. Nanobiotechnol. 3(3), 269-281 (2011).
65. Kogan MJ, Olmedo I, Hosta L, Guerrero AR, Cruz LJ, Albericio F. Peptides and metallic nanoparticles for biomedical applications. Nanomedicine 2(3), 287-306 (2007). (Pubitemid 46916297)
66. Delehanty JB, Boeneman K, Bradburne CE, Robertson K, Bongard JE, Medintz IL. Peptides for specific intracellular delivery and targeting of nanoparticles: implications for developing nanoparticle-mediated drug delivery. Ther. Deliv. 1(3), 411-433 (2010).
67. Negussie AH, Miller JL, Reddy G, Drake SK, Bradford J, Dreher MR. Synthesis and in vitro evaluation of cyclic NGR peptide targeted thermally sensitive liposome. J. Control. Release 143(2), 265-273 (2010). The cyclic cKNGRE-Oregon green conjugate bound to HT-1080 cells better than the linear analogue and the binding affinity of each peptide-Oregon green conjugate increased tenfold when bonded to lysolipid-containing temperature sensitive liposomes.
68. Morris MC, Deshayes S, Heitz F, Divita G. Cell-penetrating peptides: from molecular mechanisms to therapeutics. Biol. Cell 100(4), 201-217 (2008). (Pubitemid 351517084)
69. Kersemans V, Kersemans K, Cornelissen B. Cell penetrating peptides for in vivo molecular imaging applications. Curr. Pharm. Design 14(24), 2415-2427 (2008).
70. Kersemans V, Cornelissen B. Targeting the tumour: cell penetrating peptides for molecular imaging and radiotherapy. Pharmaceuticals 3(3), 600-620 (2010).
71. Bitler BG, Schroeder JA. Anti-cancer therapies that utilize cell penetrating peptides. Recent Pat. Anticanc. 5(2), 99-108 (2010).
72. Sugahara KN, Teesalu T, Karmali PP et al. Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science 328(5981), 1031-1035 (2010).
73. Mandal D, Nasrolahi Shirazi A, Parang K. Cell-penetrating homochiral cyclic peptides as nuclear-targeting molecular transporters. Angew. Chem. Int. Ed. 50, 9633-9637 (2011).
74. Colombo G, Curnis F, De Mori GMS et al. Structure-activity relationships of linear and cyclic peptides containing the NGR tumor-homing motif. J. Biol. Chem. 277(49), 47891-47897 (2002). (Pubitemid 36159317)
75. Mizejewski GJ, Muehlemann M, Dauphinee M. Update of a fetoprotein growth-inhibitory peptides as biotherapeutic agents for tumor growth and metastasis. Chemotherapy 52(2), 83-90 (2006).
76. Mizejewski GJ, MacColl R. α-fetoprotein growth inhibitory peptides: potential leads for cancer therapeutics. Mol. Cancer Ther. 2(11), 1243-1255 (2003).
77. Mesfin FB, Zhu S, Bennett JA, Andersen TT, Jacobson HI. Development of a synthetic cyclized peptide derived from α-fetoprotein that prevents the growth of human breast cancer. J. Pept. Res. 58(3), 246-256 (2001). (Pubitemid 32835809)
78. Woltering EA, Watson JC, Alperin-Lea C et al. Somatostatin analogs: angiogenesis inhibitors with novel mechanisms of action. Invest. New Drug 15, 77-86 (1997). (Pubitemid 27217753)
79. Baumbach WR, Carrick TA, Pausch MH et al. A linear hexapeptide somatostatin antagonist blocks somatostatin activity in vitro and influences growth hormone release in rats. Mol. Pharmacol. 54, 864-873 (1998). (Pubitemid 28523178)
80. Kwon YU, Kodadek T. Quantitative comparison of the relative cell permeability of cyclic and linear peptides. Chem. Biol. 14(6), 671-677 (2007). Linear peptides with the sequence E-Dpr-Dpr-Dpr were more permeable to HeLa cells compared with their respective cyclic analogues. (Pubitemid 46920984)
81. Fischer PM, Zhelev NZ, Wang S, Melville JE, Fåhraeus R, Lane DP. Structure-activity relationship of truncated and substituted analogues of the intracellular delivery vector Penetratin. J. Pept. Res. 55, 163-172 (2000). (Pubitemid 30079933)
82. Zhong J, Chau Y. Antitumor activity of a membrane lytic peptide cyclized with a linker sensitive to membrane type 1-matrix metalloproteinase. Mol. Cancer Ther. 7(9), 2933-2940 (2008).
83. Giblin MF, Wang N, Hoffman TJ, Jurisson SS, Quinn TP. Design and characterization of α-melanotropin peptide analogs cyclized through rhenium and technetium metal coordination. Proc. Natl Acad. Sci. USA 95(22), 12814-12818 (1998). (Pubitemid 28509480)
84. Colangelo AM, Bianco MR, Vitagliano L et al. A new nerve growth factor-mimetic peptide active on neuropathic pain in rats. J. Neurosci. 28(11), 2698-2709 (2008). (Pubitemid 351398884)
85. Greene L, Tischler A. Establishment of a norandrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth-factor. Proc. Natl Acad. Sci. USA 73(7), 2424-2428 (1976).
86. Chao MV. Neurotrophins and their receptors: a convergence point for many signalling pathways. Nat. Rev. Neurosci. 4(4), 299-309 (2003). (Pubitemid 37271375)
87. Huang E, Reichardt L. Trk receptors: roles in neuronal signal transduction. Annu. Rev. Biochem. 72, 609-642 (2003). (Pubitemid 36930455)
88. Adriaenssens E, Vanhecke E, Saule P et al. Nerve growth factor is a potential therapeutic target in breast cancer. Cancer Res. 68(2), 346-351 (2008). (Pubitemid 351380059)
89. Steiner V, Bornsen KO, Schar M et al. Analysis of synthetic peptides using matrix-assisted laser desorption ionization mass spectrometry. Peptide Res. 5(1), 25-29 (1992).
90. Liu TWB, Chen J, Zheng G. Peptide-based molecular beacons for cancer imaging and therapy. Amino Acids 41, 1123-1134 (2011).
91. Blank VC, Peña C, Roquin LP. A cyclic chimeric interferon-a2b peptide induces apoptosis in tumor cells. Cancer Biol. Ther. 6(11), 1787-1793 (2007). (Pubitemid 351590314)
92. Peña C, Blank VC, Marino VJ, Roguin LP. Synthesis and biological properties of chimeric interferon-a2b peptides. Peptides 26(7), 1144-1149 (2005). (Pubitemid 40798070)
93. Witsch EJ, Mahlknecht G, Wakim J et al. Generation and characterization of peptide mimotopes specific for anti ErbB-2 monoclonal antibodies. Int. Immunol. 23(6), 391-403 (2011).
94. Brady SF, Pawluczyk JM, Lumma PK et al. Design and synthesis of a pro-drug of vinblastine targeted at treatment of prostate cancer with enhanced efficacy and reduced systemic toxicity. J. Med. Chem. 45(21), 4706-4715 (2002).
95. Gomes P, Vale N, Moreira R. Cyclizationactivated prodrugs. Molecules 12(11), 2484-2506 (2007).